Literature DB >> 18548250

Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited.

Armando Gabrielli1, Silvia Svegliati, Gianluca Moroncini, Giovanni Pomponio, Mariarosaria Santillo, Enrico V Avvedimento.   

Abstract

Systemic sclerosis (SSc, scleroderma) is a devastating, immune-mediated, multisystem disorder characterized by microvasculature damage, circulating autoantibodies, and fibroblast activation, leading to massive fibrosis of skin, vessels, muscles, and visceral organs. Scleroderma causes disability and death as the result of end-stage organ failure. At present, no specific diagnostic nor therapeutic tools are available to handle the disease. In spite of significant effort, the etiology and pathogenesis of SSc remain obscure and, consequently, the disease outcome is unpredictable. Several years ago, Murrell suggested a unifying hypothesis linking the pathogenesis of scleroderma to the generation of a large excess of reactive oxygen species. This hypothesis has been substantiated by several reports indicating the presence of an abnormal redox state in patients with scleroderma. This review will summarize the available evidence supporting the link between free radicals and the main pathological features of scleroderma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18548250     DOI: 10.1007/s00281-008-0125-4

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  107 in total

1.  Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.

Authors:  P Sambo; D Amico; R Giacomelli; M Matucci-Cerinic; F Salsano; G Valentini; A Gabrielli
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

2.  Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.

Authors:  M Hasegawa; M Fujimoto; K Kikuchi; K Takehara
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

3.  Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features.

Authors:  A Volpe; D Biasi; P Caramaschi; W Mantovani; L M Bambara; S Canestrini; M Ferrari; G Poli; M Degan; A Carletto; S Pieropan; P Minuz
Journal:  Rheumatology (Oxford)       Date:  2005-10-11       Impact factor: 7.580

4.  A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis.

Authors:  A L Herrick; S Hollis; D Schofield; F Rieley; A Blann; K Griffin; T Moore; J M Braganza; M I Jayson
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

5.  Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

Authors:  S A Kharitonov; J B Cailes; C M Black; R M du Bois; P J Barnes
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

6.  Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis.

Authors:  Jean-Luc Cracowski; Ghainsom D Kom; Muriel Salvat-Melis; Jean-Charles Renversez; Gregg McCord; Aude Boignard; Patrick H Carpentier; Edzard Schwedhelm
Journal:  Free Radic Biol Med       Date:  2006-02-07       Impact factor: 7.376

7.  Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis.

Authors:  V M Factor; A Kiss; J T Woitach; P J Wirth; S S Thorgeirsson
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

8.  Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells.

Authors:  M Parola; M Pinzani; A Casini; E Albano; G Poli; A Gentilini; P Gentilini; M U Dianzani
Journal:  Biochem Biophys Res Commun       Date:  1993-08-16       Impact factor: 3.575

Review 9.  Vascular endothelial growth factor (VEGF) and its receptors.

Authors:  G Neufeld; T Cohen; S Gengrinovitch; Z Poltorak
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

10.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition.

Authors:  Debra F Higgins; Kuniko Kimura; Wanja M Bernhardt; Nikita Shrimanker; Yasuhiro Akai; Bernd Hohenstein; Yoshihiko Saito; Randall S Johnson; Matthias Kretzler; Clemens D Cohen; Kai-Uwe Eckardt; Masayuki Iwano; Volker H Haase
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

View more
  26 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

2.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 3.  Management of Raynaud's phenomenon and digital ischemia.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

4.  Genistein protects dermal fibrosis in bleomycin-induced experimental scleroderma.

Authors:  Süleyman Serdar Koca; Adile Ferda Dağlı; Servet Yolbaş; Nevzat Gözel; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2015-05-20

Review 5.  Innovative approaches to the therapy of fibrosis.

Authors:  Joao A de Andrade; Victor J Thannickal
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

Review 6.  Animal models of scleroderma: current state and recent development.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

7.  Cutaneous Connective Tissue Diseases: Epidemiology, Diagnosis, and Treatment.

Authors:  Bobby Y Reddy; Basil M Hantash
Journal:  Open Dermatol J       Date:  2009-01-01

8.  Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.

Authors:  Sonsoles Piera-Velazquez; Alma Makul; Sergio A Jiménez
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

Review 9.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

10.  Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis.

Authors:  Esen Savas; Nur Aksoy; Yavuz Pehlivan; Zeynel Abidin Sayiner; Zeynel Abidin Oztürk; Suzan Tabur; Mustafa Orkmez; Ahmet Mesut Onat
Journal:  Wien Klin Wochenschr       Date:  2014-05-14       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.